1,522
Views
55
CrossRef citations to date
0
Altmetric
Special Focus: Molecular and Cellular Events Controlling Neuronal and Brain Function and Dysfunction

Neuronal protein trafficking associated with Alzheimer disease

from APP and BACE1 to glutamate receptors

Pages 118-128 | Received 25 Sep 2008, Accepted 21 Oct 2008, Published online: 01 Jan 2009

Figures & data

Figure 1 Proteolytic processing of APP. A schematic depiction of APP proteolytic processing. APP is a type I transmembrane protein. The Aβ peptide domain is located partially within the membrane spanning hydrophobic segment. In amyloidogenesis, the β-secretase recognition site is cleaved by BACE1 to a soluble fragment N-terminal fragment sAPPα, a C-terminal fragment CTFβ. The latter is then cleaved intramembranously by γ-secretase to yield Aβ and the APP intracellular domain (AICD). In the non-amyloidogenic pathway, α-secretases cleave at a site within the Aβ peptide sequence. This cleavage essentially disrupts the β-secretase recognition site. α-secretases cleavage yields the soluble N-terminal sAPPα, and the C-terminal CTFα. The latter can also be cleave by γ-secretase to yield a non-toxic 3 kDa fragment known as p3, and the APP intracellular domain (AICD).

Figure 1 Proteolytic processing of APP. A schematic depiction of APP proteolytic processing. APP is a type I transmembrane protein. The Aβ peptide domain is located partially within the membrane spanning hydrophobic segment. In amyloidogenesis, the β-secretase recognition site is cleaved by BACE1 to a soluble fragment N-terminal fragment sAPPα, a C-terminal fragment CTFβ. The latter is then cleaved intramembranously by γ-secretase to yield Aβ and the APP intracellular domain (AICD). In the non-amyloidogenic pathway, α-secretases cleave at a site within the Aβ peptide sequence. This cleavage essentially disrupts the β-secretase recognition site. α-secretases cleavage yields the soluble N-terminal sAPPα, and the C-terminal CTFα. The latter can also be cleave by γ-secretase to yield a non-toxic 3 kDa fragment known as p3, and the APP intracellular domain (AICD).

Figure 2 Trafficking itinerary of APP and BACE1. A schematic diagram of the trafficking itinerary of APP and BACE1. Both proteins have very similar itinerary and can be found in compartments of the exocytic pathway and endocytic pathway. Locations of general components of membrane traffic known to affect APP/BACE1 traffic, such as gamma-ear-containing ARF-binding (GGA) proteins and the retromer complex are also shown. Although presenilins are largely localized to the ER-Golgi region at steady state, these and other components of the γ-secretase complex also have widespread presence. Note that this is a general scheme which does not include detail depiction of neuronal domains such as axons and dendrites. Dark arrows indicate exocytic or anterograde transport and white arrow endocytic or retrograde trafficking. ER, endoplasmic reticulum; ERGIC, ER-Golgi intermediate compartment; TGN, trans-Golgi network; EE, early endosome; RE, recycling endosome; LE, late endosome; L, lysosome.

Figure 2 Trafficking itinerary of APP and BACE1. A schematic diagram of the trafficking itinerary of APP and BACE1. Both proteins have very similar itinerary and can be found in compartments of the exocytic pathway and endocytic pathway. Locations of general components of membrane traffic known to affect APP/BACE1 traffic, such as gamma-ear-containing ARF-binding (GGA) proteins and the retromer complex are also shown. Although presenilins are largely localized to the ER-Golgi region at steady state, these and other components of the γ-secretase complex also have widespread presence. Note that this is a general scheme which does not include detail depiction of neuronal domains such as axons and dendrites. Dark arrows indicate exocytic or anterograde transport and white arrow endocytic or retrograde trafficking. ER, endoplasmic reticulum; ERGIC, ER-Golgi intermediate compartment; TGN, trans-Golgi network; EE, early endosome; RE, recycling endosome; LE, late endosome; L, lysosome.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.